Nabota Drives Daewoong Pharmaceutical to Record Breaking Q2 Results
Daewoong Pharmaceutical achieved its highest-ever quarterly performance in Q2, driven by a focus on new drugs and an…
카테고리 찾아보기
Bio-Pharm
"Hugel's Record-Breaking Performance Driven by Expanded Exports to China and Europe"
Market expectations are rising for Hugel following its announcement of results that far exceeded projections. Analysts…
GC's Struggles in Q2, Reversal Expected in H2?
There is a prediction in the securities industry that GC, which showed poor performance in Q2 this year, will succeed in…
Celltrion's 'Zymfentra' Listed by Big Three PBMs
Celltrion's 'Zymfentra', has been successfully listed in the formularies of all three major Pharmacy Benefit Managers…
Weight Loss of Over 20% with Obesity Drug 'Mounjaro' Approved in South Korea
The obesity treatment drug 'Mounjaro' (active ingredient: tirzepatide), which has shown powerful weight loss effects…
Samsung Faces Battery Drain Issue with Galaxy Watch
Samsung, which ambitiously announced its expansion into the healthcare sector, is now facing a significant problem with…
Hanmi Pharmaceutical's Q2 Operating Profit Up 75% To KRW 58.1 Billion
Hanmi Pharmaceutical has achieved robust performance due to strong sales of key products and the growth of its…
Daewoong Pharmaceutical's Bersiporocin Shows Positive Phase 2 Safety Data
Daewoong Pharmaceutical announced on the 29th that its new drug 'Bersiporocin', currently being developed as the world's…
ST Pharm's Shift to Deficit in H1: Will H2 Bring a Turnaround?
ST Pharm, which recorded a deficit in the first half of the year, is expected to see a rebound in performance in the…
Why Celltrion’s Retail Investors Oppose the Merger with Celltrion Pharm
“60,000 Celltrion shareholders firmly oppose the merger with Celltrion Pharm, which undermines shareholder value. We…
Will GC Biopharma's Immune Globulin 'Alyglo' Succeed in the U.S. Market?
GC Biopharma Corp's new immune globulin drug 'Alyglo' is set to enter the U.S. market after 8 years of efforts.…
Daewoong, Unveils 'One Product, One Trillion Won Revenue' Vision
Daewoong Pharmaceutical has unveiled its next growth strategy, the 'One Product, one Trillion Won Plan.' The goal is to…
Samsung Bioepis Secures FDA Approval for High-Cost Rare Disease Drug in the U.S.
Samsung Bioepis announced on the 23rd that it has received approval from the U.S. Food and Drug Administration (FDA) for…
Celltrion Finalizing Preparations for Third Plant's Commercial Production
Celltrion announced on the 23rd that its third plant, located in Songdo, Incheon, is undergoing final validation before…
Following the 'Galaxy Ring' Controversy, Samsung Faces Earphone Troubles
Samsung Electronics has decided to effectively recall its new product, 'Buds 3 Pro', following criticisms of…
GC WellBeing Anticipates Strong Market Penetration in China with Placental Injections…
GC WellBeing Corporation Expected to See Stock Price Rise in H2 with Stable Sales Growth in Chinese Market
Analysts…
"Global Clinical Trials Shift from Europe to US and China"
The focus of global clinical trials is shifting from Europe to the United States and China, according to a…
"SK Biopharm's Epilepsy Drug Excels in the U.S."... Growth Expected in the Second Half
SK Biopharm is expected to continue its performance growth in the second half of the year, driven by the stable sales…
DongA ST, Subsidiary MASH and Obesity Drug Clinical Results Expected This Year
Analysts in the securities industry suggest paying attention to the clinical results to be released later this year by…
Biosimilar Onslaught Dents Global Blockbuster Humira
The dominance of the autoimmune disease treatment Humira (active ingredient: adalimumab), once the world's best-selling…